Our unique approach starts by identifying groups of resilient individuals, such as long-term survivors of cancer or people with slow-to-progress neurodegenerative disorders.
Their antibody repertoires are then deeply sequenced, resulting in billions of antibody sequences that feed into our computational drug discovery engine.
Here we use advanced analytical tools to find groups of functionally related protective antibodies that are convergent across the resilient population only.
Convergent antibodies are selected to enter a suite of phenotypic assays that identify the antibodies with the best therapeutic properties.
These antibodies are also tested on whole human peptidome arrays to identify their targets.
This unique discovery process receives inspiration from nature to find novel drug targets and naturally-optimised therapeutic antibodies.